Tumor genetics and immune profiling guide lung cancer immunotherapy

A new review in Genes & Diseases highlights how the genetic makeup of lung tumors and their surrounding immune environment can help explain why immunotherapy works well for some patients but offers limited benefit to others. The article outlines opportunities to make treatment selection more precise for non-small cell lung cancer (NSCLC).

Prepared by a team at the First Hospital of Jilin University, the review brings together evidence on cancer-driving mutations and cellular signaling pathways that influence responses to immune checkpoint inhibitors. These medicines release molecular brakes on immune cells, helping them recognize and attack cancer. However, tumors can develop ways to evade this response.

The central message is that tumor genetics and immune characteristics should be considered together. Measuring PD-L1, a protein associated with immunotherapy response, provides useful information, but a broader assessment can reveal important differences hidden behind a single biomarker result. Genetic sequencing and immune profiling could support more individualized treatment decisions.

Among the genetic changes discussed, certain KRAS mutations, particularly when accompanied by TP53 mutations, are associated with greater immunotherapy benefit. By contrast, common EGFR mutations and ALK rearrangements often show limited responses to checkpoint inhibitors used alone. Other alterations, including STK11 and KEAP1, can contribute to an immune environment that resists treatment, underscoring the importance of examining combinations of mutations.

The review also explores strategies to reshape the tumor microenvironment, the network of immune cells, supporting cells and molecules surrounding a tumor. Blocking the CD73/adenosine pathway could help reduce immune suppression, while activating STING signaling may strengthen immune recognition. Approaches involving DNA damage repair and other signaling networks offer additional possibilities for improving responses to checkpoint blockade.

Combining immunotherapy with targeted medicines or chemotherapy may offer advantages in selected settings. However, the article emphasizes that combinations require careful evaluation: some pairings can cause substantial liver toxicity or lung inflammation. Potential benefit therefore needs to be balanced against treatment risks, mutation subtype and previous therapy.

For patients whose cancer stops responding, the review proposes repeat genetic and biomarker assessment to help identify changes that could inform subsequent treatment choices. Several emerging combinations remain experimental, and their value requires further clinical validation.

Source:
Journal reference:

Liu, C., et al. (2026) Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC. Genes & Diseases. DOI: 10.1016/j.gendis.2026.102230. https://www.sciencedirect.com/science/article/pii/S2352304226002023?via%3Dihub

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Chronic stress promotes oral cancer through a brain–immune pathway